MHC loss in colorectal tumours: Evidence for immunoselection?

L. Kaklamanis, Ann Hill

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The reason for MHC loss in colorectal tumours remains uncertain. Strong evidence that the downregulation is due to immunoselective pressure would be provided by the finding of deletions or mutations directly involving MHC heavy chain or β2m genes. However, although in contrast to studies on cell lines (Brodsky et al, 1979a; Travers et al, 1986; D'Urso et al, 1991), our findings are in agreement with other evidence (Doyle et al, 1985; Blanchet et al, 1990; Henseling et al, 1990) that the most common mechanism of downregulation is regulatory, mostly at a transcriptional level. Does this imply that MHC loss in tumours can be incidental? The answer to this question will depend on the nature of the initial lesion identified. The existence of cis-acting regulatory mechanisms and dominant negative trans-acting mechanisms suggests that a single mutational event could result in transcriptional changes affecting a number of genes. Thus, selective pressure could result in tumour variants whose loss of MHC is due to transcriptional regulatory changes. As these mechanisms are unravelled, it may be possible to draw conclusions about the aetiology of MHC loss in colorectal tumours. Meanwhile, in the absence of demonstrated CTL to colorectal tumours, the case for immunoselective pressure remains unproven.

Original languageEnglish (US)
Pages (from-to)155-171
Number of pages17
JournalCancer Surveys
Volume13
StatePublished - 1992
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Down-Regulation
Pressure
Sequence Deletion
Genes
Neoplasms
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

MHC loss in colorectal tumours : Evidence for immunoselection? / Kaklamanis, L.; Hill, Ann.

In: Cancer Surveys, Vol. 13, 1992, p. 155-171.

Research output: Contribution to journalArticle

@article{0fcbd6583f2e4cad9c606cf55ae2ddd8,
title = "MHC loss in colorectal tumours: Evidence for immunoselection?",
abstract = "The reason for MHC loss in colorectal tumours remains uncertain. Strong evidence that the downregulation is due to immunoselective pressure would be provided by the finding of deletions or mutations directly involving MHC heavy chain or β2m genes. However, although in contrast to studies on cell lines (Brodsky et al, 1979a; Travers et al, 1986; D'Urso et al, 1991), our findings are in agreement with other evidence (Doyle et al, 1985; Blanchet et al, 1990; Henseling et al, 1990) that the most common mechanism of downregulation is regulatory, mostly at a transcriptional level. Does this imply that MHC loss in tumours can be incidental? The answer to this question will depend on the nature of the initial lesion identified. The existence of cis-acting regulatory mechanisms and dominant negative trans-acting mechanisms suggests that a single mutational event could result in transcriptional changes affecting a number of genes. Thus, selective pressure could result in tumour variants whose loss of MHC is due to transcriptional regulatory changes. As these mechanisms are unravelled, it may be possible to draw conclusions about the aetiology of MHC loss in colorectal tumours. Meanwhile, in the absence of demonstrated CTL to colorectal tumours, the case for immunoselective pressure remains unproven.",
author = "L. Kaklamanis and Ann Hill",
year = "1992",
language = "English (US)",
volume = "13",
pages = "155--171",
journal = "Cancer Surveys",
issn = "0261-2429",
publisher = "Cold Spring Harbor Laboratory Press",

}

TY - JOUR

T1 - MHC loss in colorectal tumours

T2 - Evidence for immunoselection?

AU - Kaklamanis, L.

AU - Hill, Ann

PY - 1992

Y1 - 1992

N2 - The reason for MHC loss in colorectal tumours remains uncertain. Strong evidence that the downregulation is due to immunoselective pressure would be provided by the finding of deletions or mutations directly involving MHC heavy chain or β2m genes. However, although in contrast to studies on cell lines (Brodsky et al, 1979a; Travers et al, 1986; D'Urso et al, 1991), our findings are in agreement with other evidence (Doyle et al, 1985; Blanchet et al, 1990; Henseling et al, 1990) that the most common mechanism of downregulation is regulatory, mostly at a transcriptional level. Does this imply that MHC loss in tumours can be incidental? The answer to this question will depend on the nature of the initial lesion identified. The existence of cis-acting regulatory mechanisms and dominant negative trans-acting mechanisms suggests that a single mutational event could result in transcriptional changes affecting a number of genes. Thus, selective pressure could result in tumour variants whose loss of MHC is due to transcriptional regulatory changes. As these mechanisms are unravelled, it may be possible to draw conclusions about the aetiology of MHC loss in colorectal tumours. Meanwhile, in the absence of demonstrated CTL to colorectal tumours, the case for immunoselective pressure remains unproven.

AB - The reason for MHC loss in colorectal tumours remains uncertain. Strong evidence that the downregulation is due to immunoselective pressure would be provided by the finding of deletions or mutations directly involving MHC heavy chain or β2m genes. However, although in contrast to studies on cell lines (Brodsky et al, 1979a; Travers et al, 1986; D'Urso et al, 1991), our findings are in agreement with other evidence (Doyle et al, 1985; Blanchet et al, 1990; Henseling et al, 1990) that the most common mechanism of downregulation is regulatory, mostly at a transcriptional level. Does this imply that MHC loss in tumours can be incidental? The answer to this question will depend on the nature of the initial lesion identified. The existence of cis-acting regulatory mechanisms and dominant negative trans-acting mechanisms suggests that a single mutational event could result in transcriptional changes affecting a number of genes. Thus, selective pressure could result in tumour variants whose loss of MHC is due to transcriptional regulatory changes. As these mechanisms are unravelled, it may be possible to draw conclusions about the aetiology of MHC loss in colorectal tumours. Meanwhile, in the absence of demonstrated CTL to colorectal tumours, the case for immunoselective pressure remains unproven.

UR - http://www.scopus.com/inward/record.url?scp=0026623332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026623332&partnerID=8YFLogxK

M3 - Article

C2 - 1423322

AN - SCOPUS:0026623332

VL - 13

SP - 155

EP - 171

JO - Cancer Surveys

JF - Cancer Surveys

SN - 0261-2429

ER -